True transformation requires AI that links customer data, knowledge bases, and operational systems to enable intelligent ...

Clever Culture’s APAS is now on trial with Novo Nordisk, and if it delivers, this one machine could unlock a ... Read More ...

AstraZeneca PLC closed 21.60% below its 52-week high of £133.88, which the company achieved on September 3rd.

Sino Biopharmaceuticals plans to pay up to $950.9 million to acquire LaNova Medicines, which previously licensed drugs to ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research ...

AstraZeneca PLC (NASDAQ:AZN) is one of Goldman Sachs’ top healthcare stock picks. On July 4, the company secured regulatory ...

Proposals by Robert F. Kennedy Jr. and Bernie Sanders range from more disclosures in commercials to an outright ban.

Days after JCR Pharmaceuticals signed a deal with AstraZeneca’s rare disease unit, the Japanese biopharma has secured a ...

Positive high-level results in trials of its baxdrostat drug to treat hypertension provided AstraZeneca shares with a ...

AstraZeneca’s drug candidate baxdrostat lowered systolic blood pressure in a phase 3 clinical trial involving patients with uncontrolled or treatment-resistant hypertension. In the trial, patients who ...

The BaxHTN study met its primary endpoint, and researchers will present more data at the ESC Congress later this summer.

Manufacturing issues are the latest problem for Ultragenyx Pharmaceutical Inc. to solve after last week’s disappointment in a phase III study to treat brittle bones. The U.S. FDA gave the company a ...